CGON · CG Oncology, Inc. Common stock

CG Oncology reported first-quarter 2026 results reflecting the transition toward revenue generation amid escalating clinical development costs. Revenue reached $1.1 million, up 1982.7% from $52 thousand in the prior-year quarter, primarily from Biovire's fill/finish services for commercial and development product sales following the July 2025 acquisition. This emergence marks a shift from historical patterns where the company generated no revenue from product sales of cretostimogene since inception.

Operating costs and expenses, comprising cost of sales, research and development (R&D), and general and administrative expenses, drove operating income deeper into deficit at -$66.4 million, a 57.3% worsening from -$42.2 million. Product candidates in later stages of clinical development incur higher costs due to the increased size and duration of trials, explaining the intensified R&D spend as external and internal activities advance clinical and preclinical efforts. Cost of sales captures direct labor, manufacturing, production, and packaging materials tied to these nascent sales. Net income followed suit at -$60.2 million, 74.7% below prior-year -$34.5 million, with diluted EPS at -$0.71 versus -$0.45.

Cash flow from operations consumed -$56.9 million, doubling from -$29.3 million, leading to free cash flow of -$57.2 million after $0.3 million in capital expenditures. These negative cash flows from operations persist as characteristic of the company's clinical-stage profile, funding ongoing and planned development without sustainable product revenue.

Looking forward, R&D expenses are expected to rise substantially with ongoing clinical and preclinical activities, while general and administrative costs will increase to support operations expansion, headcount growth, and commercialization preparation for cretostimogene. This positions the company to advance late-stage programs despite near-term loss intensification, balancing revenue initiation with investment demands.